INMB earnings call for the period ending June 30, 2022.
Company to Host Conference Call Today, August 3, at 4:30pm ET...
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc....
Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings,...
In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03™ decreases MUC4 expression, reverses resistance to...
BOCA RATON, FL., May 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...
INMB earnings call for the period ending March 31, 2022.
Company Dosed First Phase 2 Mild Alzheimer’s Disease Patient with Xpro1595; Presented Data from Ongoing INKmune™ Studies Suggesting Increased NK Cell...
Management to host conference call and webcast at 4:30 pm ET on that day...
Boca Raton, FL, April 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that...